Atossa Therapeutics Executive Compensation Details
Ticker: ATOS · Form: DEF 14A · Filed: Mar 26, 2025 · CIK: 1488039
| Field | Detail |
|---|---|
| Company | Atossa Therapeutics, INC. (ATOS) |
| Form Type | DEF 14A |
| Filed Date | Mar 26, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
Related Tickers: ATOS
TL;DR
Atossa's DEF 14A is out, showing exec pay details for 2024. Focus on equity awards for NEOs & Non-NEOs.
AI Summary
Atossa Therapeutics, Inc. filed a DEF 14A on March 26, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to Named Executive Officers (NEOs) and Non-NEOs, with specific data points on the change in fair value of outstanding and unvested equity awards for both groups during the covered year.
Why It Matters
This filing provides transparency into how Atossa Therapeutics compensates its top executives, which can influence investor perception and company strategy.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures about executive compensation, but significant changes or high compensation figures can indicate potential risks related to corporate governance or shareholder value.
Key Numbers
- 2024 — Fiscal Year End (Executive compensation data pertains to this period.)
- 20250326 — Filing Date (Date the DEF 14A was submitted to the SEC.)
Key Players & Entities
- Atossa Therapeutics, Inc. (company) — Filer
- Steven C. Quay (person) — Member of the Board of Directors
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to disclose information regarding the solicitation of proxies for the company's annual meeting of shareholders, including details on executive compensation.
What fiscal year does the executive compensation data primarily cover?
The executive compensation data primarily covers the fiscal year ending December 31, 2024.
Who are the key individuals or groups whose compensation is detailed in this filing?
The filing details compensation for Named Executive Officers (NEOs) and Non-NEOs (Non-Principal Executive Officers).
What specific types of compensation are highlighted in the filing?
The filing highlights equity awards, including their fair value, changes in fair value, and vesting dates.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on March 26, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on March 26, 2025 by Steven C. Quay regarding ATOSSA THERAPEUTICS, INC. (ATOS).